Company profile
TARSUS PHARMACEUTICALS, INC.
NASDAQ:TARSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| XDEMVY | approved | $173.9MQ2 2026 | 2 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05387083 | phase2 | completed | 2022-12-12 | 2024-06-26 | Tarsus Pharmaceuticals, Inc. | A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 |
| NCT05138796 | phase1 | completed | 2021-05-06 | 2022-03-25 | Tarsus Pharmaceuticals, Inc. | A Pharmacokinetic Study of TP-05 in Healthy Subjects |
| NCT05138861 | phase1 | completed | 2021-02-09 | 2021-09-03 | Tarsus Pharmaceuticals, Inc. | A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects |
| NCT07562087 | phase2 | active_not_recruiting | 2026-03-09 | 2027-10-01 | Tarsus Pharmaceuticals, Inc. | A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure |
| NCT06054217 | phase2 | unknown | 2023-08-01 | 2024-06-15 | Tarsus Pharmaceuticals, Inc. | Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 217603 | 2023-07-24 | NDA | TARSUS PHARMACEUTICALS INC | |||||
Loading… | ||||||||